159 related articles for article (PubMed ID: 37303494)
1. The Implication of microRNAs as non-invasive biomarkers in 179 Egyptian breast cancer female patients.
Shaaban NZ; Ibrahim NK; Saada HN; El-Rashidy FH; Shaaban HM; Elbakary NM; Kodous AS
Oncol Res; 2022; 30(6):269-276. PubMed ID: 37303494
[TBL] [Abstract][Full Text] [Related]
2. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
[TBL] [Abstract][Full Text] [Related]
3. Dual biomarkers long non-coding RNA GAS5 and microRNA-34a co-expression signature in common solid tumors.
Toraih EA; Alghamdi SA; El-Wazir A; Hosny MM; Hussein MH; Khashana MS; Fawzy MS
PLoS One; 2018; 13(10):e0198231. PubMed ID: 30289954
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis.
Javeri A; Ghaffarpour M; Taha MF; Houshmand M
Med Oncol; 2013 Mar; 30(1):413. PubMed ID: 23292869
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of miRNA-9 and miRNA-34a as potential biomarkers for diagnosis of breast cancer in Iranian women.
Orangi E; Motovali-Bashi M
Gene; 2019 Mar; 687():272-279. PubMed ID: 30468908
[TBL] [Abstract][Full Text] [Related]
6. MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer.
Peurala H; Greco D; Heikkinen T; Kaur S; Bartkova J; Jamshidi M; Aittomäki K; Heikkilä P; Bartek J; Blomqvist C; Bützow R; Nevanlinna H
PLoS One; 2011; 6(11):e26122. PubMed ID: 22102859
[TBL] [Abstract][Full Text] [Related]
7. Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.
Li G; Yao L; Zhang J; Li X; Dang S; Zeng K; Zhou Y; Gao F
Tumour Biol; 2016 Jun; 37(6):7481-91. PubMed ID: 26678891
[TBL] [Abstract][Full Text] [Related]
8. Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells.
Hargraves KG; He L; Firestone GL
Mol Carcinog; 2016 May; 55(5):486-98. PubMed ID: 25789847
[TBL] [Abstract][Full Text] [Related]
9. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
10. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.
Li L; Yuan L; Luo J; Gao J; Guo J; Xie X
Clin Exp Med; 2013 May; 13(2):109-17. PubMed ID: 22623155
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion.
Wu X; Cheng YL; Matthen M; Yoon A; Schwartz GK; Bala S; Taylor AM; Momen-Heravi F
J Exp Clin Cancer Res; 2021 Feb; 40(1):70. PubMed ID: 33596979
[TBL] [Abstract][Full Text] [Related]
12. MiR-34a is up-regulated in response to low dose, low energy X-ray induced DNA damage in breast cells.
Stankevicins L; Almeida da Silva AP; Ventura Dos Passos F; Dos Santos Ferreira E; Menks Ribeiro MC; G David M; J Pires E; Ferreira-Machado SC; Vassetzky Y; de Almeida CE; de Moura Gallo CV
Radiat Oncol; 2013 Oct; 8():231. PubMed ID: 24094113
[TBL] [Abstract][Full Text] [Related]
13. Expanding the Biotherapeutics Realm via miR-34a: "Potent Clever Little" Agent in Breast Cancer Therapy.
Mohammady M; Ghetmiri SI; Baharizade M; Morowvat MH; Torabi S
Curr Pharm Biotechnol; 2019; 20(8):665-673. PubMed ID: 31244419
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer.
Sandhu R; Rivenbark AG; Mackler RM; Livasy CA; Coleman WB
Int J Oncol; 2014 Feb; 44(2):563-72. PubMed ID: 24297604
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.
He M; Gao L; Zhang S; Tao L; Wang J; Yang J; Zhu M
Gastric Cancer; 2014; 17(3):431-41. PubMed ID: 24232982
[TBL] [Abstract][Full Text] [Related]
16. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.
Eichelser C; Flesch-Janys D; Chang-Claude J; Pantel K; Schwarzenbach H
Clin Chem; 2013 Oct; 59(10):1489-96. PubMed ID: 23748853
[TBL] [Abstract][Full Text] [Related]
17. Micro RNA 34a and Let-7a Expression in Human Breast Cancers is Associated with Apoptotic Expression Genes.
Mansoori B; Mohammadi A; Shirjang S; Baghbani E; Baradaran B
Asian Pac J Cancer Prev; 2016; 17(4):1887-90. PubMed ID: 27221871
[TBL] [Abstract][Full Text] [Related]
18. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients.
Khalighfard S; Alizadeh AM; Irani S; Omranipour R
Sci Rep; 2018 Dec; 8(1):17981. PubMed ID: 30568292
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome.
Medimegh I; Omrane I; Privat M; Uhrhummer N; Ayari H; Belaiba F; Benayed F; Benromdhan K; Mader S; Bignon IJ; Elgaaied AB
PLoS One; 2014; 9(11):e111877. PubMed ID: 25369070
[TBL] [Abstract][Full Text] [Related]
20. The RNA-binding protein SART3 promotes miR-34a biogenesis and G
Sherman EJ; Mitchell DC; Garner AL
J Biol Chem; 2019 Nov; 294(46):17188-17196. PubMed ID: 31619517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]